Medivir (MVIR) Study Result summary
Event summary combining transcript, slides, and related documents.
Study Result summary
16 Oct, 2026Phase 1b findings
Completed dose-escalation results from the phase 1b monotherapy study presented at ESMO; 9 evaluable patients with advanced liver cancers had exhausted approved therapies.
Safety profile aligned with expectations for this drug and patient population.
Four patients with HCC had stable disease in the liver over an extended period.
Liver biopsies showed MIV-818 delivery to the liver and a selective effect on cancer cells across cancer types.
Development plans
MIV-818 is an oral prodrug designed to selectively treat liver cancers and minimize side effects.
An HCC combination study was planned to start in H2 2021; further development would explore combinations with two other mechanisms of action.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Medivir
- SEK 247.9m cash supports three Phase II programs, with FLEX-HCC readout expected in 2027.MVIR
Q3 2026 - Fostrox plus lenvatinib showed early disease control in phase Ib HCC patients.MVIRStudy Update
- SEK 148m rights issue backs fostrox’s next HCC development steps.MVIRInvestor Update
- Three phase 2 studies fully funded, targeting high-value markets in liver cancer and rare bone diseases.MVIRCompany presentation
- SEK 140 million raised, three phase II studies funded, and positive fostrox clinical results.MVIRQ2 2026
- Fostrox + Lenvima delivers best-in-class efficacy for 2nd line HCC, targeting a $2.5bn+ market.MVIRDNB Nordic Healthcare Conference presentation
- Fostrox plus lenvatinib delivers superior efficacy and safety in second-line advanced liver cancer.MVIRPareto Securities Healthcare Conference presentation
- Fostrox + Lenvima shows promising efficacy in 2nd line HCC, targeting a major unmet need.MVIRCarnegie Småbolagsdag 2024
- Fostrox plus lenvatinib achieved 24% ORR in advanced HCC; randomized phase 2b is planned.MVIRStatus Update